Company profile: MDNA Life Sciences
1.1 - Company Overview
Company description
- Provider of proprietary, blood-based diagnostic tests leveraging mitochondrial DNA to improve early disease detection, diagnosis, treatment, prognosis and monitoring. Offerings include the Mitomic Prostate Test (3.4 kb deletion to assess significant prostate cancer risk and aid biopsy decisions) and Mitomic Endometriosis Test (8.7 kb deletion to reduce diagnostic delays), powered by Mitomic Technology to detect disease-specific mtDNA biomarkers with high sensitivity and specificity.
Products and services
- Mitomic™ Technology: Proprietary platform that detects disease-specific mitochondrial DNA biomarkers via blood tests, improving early disease detection and monitoring
- Mitomic™ Tests: A portfolio of blood-based tests for early detection of various cancers and endometriosis, delivering high sensitivity and specificity to aid diagnosis, treatment, prognosis, and monitoring
- Mitomic™ Prostate Test: A mitochondrial DNA–based blood test measuring the 3.4 kb deletion to stratify risk of significant prostate cancer, guiding biopsy decisions.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MDNA Life Sciences
Eleison Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage oncology drug candidates for orphan cancers through acquisition, development, and commercialization, including Glufosfamide (glucose-linked ifosforamide mustard targeting cancer cells to reduce normal-cell toxicity), Inhaled Lipid-Complexed Cisplatin for lung diseases (prolonged effect, enhanced uptake, reduced systemic toxicity), and Dibromodulcitol requiring further safety-equivalence studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eleison Pharmaceuticals company profile →
RainDance Technologies
HQ: United States
Website
- Description: Provider of medical technology solutions leveraging droplet technology for research in areas including non-invasive liquid biopsy, and offering molecules, single-cell analyses, reaction methodology, cancer research, mutation detection, and diagnostics services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RainDance Technologies company profile →
ViraTherapeutics
HQ: Austria
Website
- Description: Provider of oncolytic virus-based anti-cancer therapeutics, including VSV-GP, a modified Vesicular Stomatitis Virus designed to selectively destroy cancer cells while sparing normal tissues. Offers preclinical safety and efficacy studies for VSV-GP and plans clinical trials to evaluate its therapeutic potential in cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ViraTherapeutics company profile →
PCI Biotech
HQ: Norway
Website
- Description: Provider of photochemical drug delivery technologies for cancer therapy, focusing on photochemical internalisation (PCI) to enhance intracellular delivery of therapeutic compounds for novel cancer treatments, and photochemical lysis (PCL) to improve viral vector manufacturing through light-triggered cell lysis that increases yield and reduces impurities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PCI Biotech company profile →
Iambic Therapeutics
HQ: United States
Website
- Description: Provider of an AI-driven drug-discovery platform to optimize drug profiles and identify novel mechanisms of action, featuring NeuralPlexer (3D physics-based generative diffusion for protein-ligand structures), OrbNet (protein-ligand binding energetics), PropANE (multi-parameter lead selection), and Magnet (generative molecular design), plus a first-in-class CDK2/4 candidate for cyclin D- and E-driven cancers with reduced off-target toxicities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iambic Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MDNA Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MDNA Life Sciences
2.2 - Growth funds investing in similar companies to MDNA Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MDNA Life Sciences
4.2 - Public trading comparable groups for MDNA Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →